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Radiation has emerged as the most critical issue to be resolved for long-term missions both 
orbital and interplanetary. Astronauts are constantly exposed to galactic cosmic radiation 
(GCR) of various energies with a low dose rate. Primarily late tissue sequels like genetic 
alterations, cancer and non-cancer effects, i.e. cataracts and degenerative diseases of e.g. 
the central nervous system or the cardiovascular system, are the potential risks. Cataracts 
were observed to occur earlier and more often in astronauts exposed to higher proportions 
of galactic ions (Cucinotta et al., 2001). Predictions of cancer risk and acceptable radiation 
exposure in space are subject to many uncertainties including the relative biological 
effectiveness (RBE) of space radiation especially heavy ions, dose-rate effects and possible 
interaction with microgravity and other spaceflight environmental factors. The initial cellular 
response to radiation exposure paves the way to late sequelae and starts with damage to 
the DNA which complexity depends on the linear energy transfer (LET) of the radiation. 
Repair of such complex DNA damage is more challenging and requires more time than the 
repair of simple DNA double strand breaks (DSB) which can be visualized by 
immunofluorescence staining of the phosphorylated histone 2AX (γH2AX) and might explain 
the observed prolonged cell cycle arrests induced by high-LET in comparison to low-LET 
irradiation. Unrepaired or mis-repaired DNA DSB are proposed to be responsible for cell 
death, mutations, chromosomal aberrations and oncogenic cell transformation. Cell killing 
and mutation induction are most efficient in an LET range of 90-200 keV/µm. Also the 
activation of transcription factors such as Nuclear Factor κB (NF-κB) and gene expression 
shaping the cellular radiation response depend on the LET with a peak RBE between 90 and 
300 keV/µm. Such LET-RBE relationships were observed for cataract and cancer induction by 
heavy ions in laboratory animals, with varying maximal efficiencies. Furthermore, there is 
always the added risk of acute exposure to high proton fluxes during a solar particle event 
(SPE), which can threaten immediate survival of the astronauts in case of insufficient 
shielding by eliciting the acute radiation syndrome. Its symptoms depend on absorbed total 
radiation dose, type of radiation, the dose distribution in the body and the individual 
radiation sensitivity. After the prodromal stage with nausea and vomiting and a subsequent 
symptom-free phase, depending on dose, the hematopoietic syndrome with suppression of 
the acquired immune system and thrombocytopenia (0.7-4 Sv), the gastrointestinal tract 
syndrome (5-12 Sv) or the central nervous system syndrome (> 20 Sv) develop and they are 
accompanied by exacerbated innate immune responses. Exposure to large SPE has to be 
avoided by warning systems and stay inside a radiation shelter during the event. Treatment 
options encompass e.g. the administration of colony-stimulating factors (CSF), growth 
factors and blood transfusions to overcome the hematopoietic syndrome and the 
administration of antibiotics against secondary infections. A concerted action of ground-
based studies and space experiments is required to improve the radiobiological basis of 
space radiation risk assessment and countermeasure development. 
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